PT - JOURNAL ARTICLE AU - MOTOYUKI SUZUKI AU - YUKINORI TAKENAKA AU - TOSHIHIRO KISHIKAWA AU - YOSHIFUMI YAMAMOTO AU - ATSUSHI HANAMOTO AU - YOICHIRO TOMIYAMA AU - TAKAHITO FUKUSUMI AU - TAKAHIRO MICHIBA AU - NORIHIKO TAKEMOTO AU - SUSUMU NAKAHARA AU - HIDENORI INOHARA TI - Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer AID - 10.21873/anticanres.14973 DP - 2021 Apr 01 TA - Anticancer Research PG - 2045--2051 VI - 41 IP - 4 4099 - http://ar.iiarjournals.org/content/41/4/2045.short 4100 - http://ar.iiarjournals.org/content/41/4/2045.full SO - Anticancer Res2021 Apr 01; 41 AB - Background/Aim: To retrospectively evaluate the efficacy and safety of modified TPEx (docetaxel 60 mg/m2 on day 1, cisplatin 60 mg/m2 on day 1, and weekly cetuximab 250 mg/m2 with loading dose of 400 mg/m2) followed by maintenance cetuximab as first-line treatment for inoperable recurrent and/or metastatic squamous cell carcinoma of the head and neck. Patients and Methods: We analyzed 22 Japanese patients receiving modified TPEx every 21 days for four cycles with or without prophylactic granulocyte colony-stimulating factor (G-CSF). Results: The best overall response rate was 55% [95% confidence interval (CI)=35-73]. The median progression-free survival and overall survival were 8.9 months (95%CI=3.9-10.2) and 14.3 months (95%CI=10.1-28.2), respectively. Without prophylactic G-CSF, Grade 3/4 neutropenia and febrile neutropenia was common (94% versus 20%; p=0.003 and 41% versus 0%; p=0.11, respectively). Conclusion: The modified TPEx is effective, while prophylactic G-CSF is essential.